Donepezil use in managed Medicare: Effect on health care costs and utilization

Clinical Therapeutics

Volumn 21, Issue 12, 1999, Pages 2173-2185

  Fillit, Howard ^a,d   Gutterman, Elane M ^b   Lewis, Barbara ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Consumer Health Sciences ^*  (United States)

^c Focus Managed Research   (United States)

^d Alzheimers Drug Discovery Foundation   (United States)

Author keywords

Alzheimer's disease; Dementia; Disease management; Donepezil; Health care financing; Managed care; Medicare

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; DEMENTIA; DRUG USE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; PRESCRIPTION;

EID: 0033395458     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)87246-X     Document Type: Article

References (43)

1. 1. Fillit HM, Knopman D, Cummings J, Appel F. Opportunities for improving managed care for individuals with dementia: Part I. The issues. Am J Managed Care. 1999;5:309-315.
2. 2. Foster RH, Plosker GL. Donepezil: Pharmacoeconomic implications of therapy. Pharmacoeconomics. 1999;16:99-114.
3. 3. Eppig FJ, Poisal JA. Mental health of Medicare beneficiaries. Health Care Financ Rev. 1997;18:207-210.
4. 4. Fishman P, Von Korff M, Lozano P, Hecht J. Chronic care costs in managed care. Health Aff. 1997;16;239-247.
5. 5. Gutterman EG, Markowitz JM, Lewis B, Fillit H. Cost of Alzheimer's disease and related dementia in managed-Medicare. J Am Geriatr Soc. 1999;47:1065-1071.
6. 6. Menzin J, Lang K, Friedman M, et al. The economic cost of Alzheimer's disease and related dementia to the California Medicaid program (Medi-Cal) in 1995. Am J Geriatr Psychiatry. 1999;7:300-308.
7. 7. Weiner M, Powe NR, Weller WE, et al. Alzheimer's disease under managed care: Implications from Medicare utilization and expenditure patterns. J Am Geriatr Soc. 1998;46:762-770.
8. 8. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer disease. Arch Neurol. 1997;54:687-693.
9. 9. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 1999;52:1138-1145.
10. 10. O'Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc. 1999;47:570-578.
11. 11. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther. 1998;20:838-850.
12. 12. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer's disease. Lancet. 1997;350:232-233.
13. 13. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158:1021-1031.
14. 14. Rogers SL, Farlow MR, Doody RS, et al, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
15. 15. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
16. 16. Leber P. Guidelines for the Clinical Evaluation of Antidementia Drugs. Rockville, Md: US Food and Drug Administration; 1990.
17. 17. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84:1261-1264.
18. 18. Huang L, Cartwright WS, Hu T. The economic cost of senile dementia in the United States, 1985. Public Health Rep. 1988;103:3-7.
19. 19. Wimo A, Ljunggren G, Winblad B. Costs of dementia and dementia care: A review. Int J Geriatr Psychiatry. 1997; 12:841 -856.
20. 20. Torian L, Davidson E, Fulop G, et al. The effect of dementia on acute care in a geriatric medical unit. Int Psychogeriatr. 1992;4:231-239.
21. 21. Welch HG, Walsh JS, Larson EB. The cost of institutional care in Alzheimer's disease: Nursing home and hospital use in a prospective cohort. J Am Geriatr Soc. 1992;40:221-224.
22. 22. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology. 1996;47:166-177.
23. 23. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159-1165.
24. 24. Lamphere JA, Neuman P, Langwell K, Sherman D. The surge in Medicare managed care: An update. Health Aff. 1997; 16:127-133.
25. 25. US Department of Health and Human Services. Growth in Medicare managed care enrollment: Cys 1985-96. Health Care Financ Rev 1996: Statistical Supplement. 1996;18:126-127.
26. 26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373-382.
27. 27. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
28. 28. Barber JA, Thompson SG. Analysis and interpretation of cost data in randomised controlled trials: Review of published studies. Br Med J. 1998;317:1195-1200.
29. 29. Siegel S, Castellan NJ. Nonparametric Statistics for the Behavioral Sciences. 2nd ed. New York: McGraw-Hill Book Co; 1988:68-75.
30. 30. Arno PS, Levine C, Memmott MM. The economic value of informal caregiving. Health Aff. 1999;18:182-188.
31. 31. Schulz R, O'Brien AT, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes. Gerontologist. 1995;35:771-791.
32. 32. Fillit HM, Knopman D, Cummings J, Appel F. Opportunities for improving managed care for individuals with dementia: Part 2. A framework for care. Am J Managed Care. 1999;5:317-324.
33. 33. Leon J, Cheng C-K, Neumann PJ. Alz-heimer's disease care: Costs and potential savings. Health Aff. 1998;17:206-216.
34. 34. Mechanic D. The experience and expression of distress: The study of illness behavior and medical utilization. In: Mechanic D, ed. Handbook of Health, Health Care, and the Health Professions. New York: The Free Press; 1983:591-607.
35. 35. Devanand DP, Jacobs DM, Tang M-X, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257-263.
36. 36. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46:130-135.
37. 37. Geldmacher DS, Whitehouse PJ. Evaluation of dementia. N Engl J Med. 1996; 335:330-336.
38. 38. Mushlin AI. Disease, drugs, decisions, and dollars. Neurology. 1999;52:1115-1116. Editorial.
39. 39. Evans DA, Scherr PA, Cook NR, et al. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 1990;68:267-289.
40. 40. Greene VL, Ondrich J, Laditka S. Can home care services achieve cost savings in longterm care for older people? J Gerontology B Psychol Sci Soc Sci. 1998;53:S228-S238.
41. 41. Mittelman MS, Ferris SH, Shulman E, et al. A family intervention to delay nursing home placement of patients with Alzheimer disease. JAMA. 1996;276;1725-1731.
42. 42. Mukamel DB, Chou C, Zimmer JG, Roethenberg BM. The effect of accurate patient screening on the cost-effectiveness of case management programs. Gerontologist. 1997;37:777-784.
43. 43. Philp I, McKee KJ, Meldrum P, et al. Community care for demented and nondemented elderly people: A comparison study of financial burden, service use, and unmet needs in family supporters. Br Med J. 1995;310:1503-1506.